 |
Prospector
Profile
07.1095
|
| |
| Kyto Biopharma, Inc. |
NAICS |
541710 |
| B1-114 Belmont
Toronto, Ontario, Canada M5R 1P8 |
Description |
Biotechnology |
| (416) 955-0349 |
Employees |
0 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-4.1480 |
| |
Assets |
(mil) |
0.0180 |
| |
Liability |
(mil) |
0.4430 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Jewett Schwartz Wolfe & Associates raised substantial doubt about Kyto Biopharma, Inc.'s ability to continue as a going concern due to its need to seek new sources or methods of financing or revenue to pursue its business strategy. In fiscal year 2007, the Company had a net loss of $4,148,725, cash used in operations of $169,531, a working capital deficiency of $425,005, a stockholders' deficiency of $425,005, and a deficit accumulated during development stage of $15,477,735.
|
| |
|
Intellectual Property:
Kyto's patent strategy has been to develop an "umbrella" of patents protecting its core technology and their therapeutic uses and the underlying technologies used to create them. The Company has filed a number of patent applications in the United States, the PCT Member Countries, Japan, and in most other jurisdictions to protect its proprietary rights in the development of its technologies and products. To date, 18 patents have been issued. Kyto is co-assignee on the issued and pending patents along with different universities. [SEC Filing 10-KSB 07-02-07]
|
| |
|
Description:
The Company develops receptor-mediated technologies to control the uptake of vitamin B12 by non-controlled proliferative cells.
|
| |
|
Officers:
Georges Benarroch (Pres., CEO & Dir.); Don MacAdam (Dir.); Jean-Luc Berger, Ph.D. (Dir.)
|
| |
|
Auditor:
Jewett Schwartz Wolfe & Associates
|
| |
|
Securities:
Common Stock-Symbol KBPH.OB; OTC BB;
12,080,203 common shares outstanding as of March 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
